Zobrazeno 1 - 10
of 68
pro vyhledávání: '"R M, Egeler"'
Autor:
Tal Schechter, Adam Gassas, R M Egeler, E McDougall, Sarah Courtney, W Lau, Muhammad Ali, K Patrick, Joerg Krueger, Christine Armstrong, John Doyle
Publikováno v:
Bone Marrow Transplantation. 50:536-539
Major ABO incompatible BM transplantation carries a risk of acute haemolysis. Red cell depletion reduces this risk but not all incompatible RBC (iRBCs) are removed and in children the residual volume can be significant relative to body weight. We sou
Autor:
Juul T. Wijnen, Tom Revesz, R M Egeler, M.J.D. van Tol, Marco W. Schilham, A.C. Lankester, V H J van der Velden, B. Versluys, Annemarie J. M. Wijkhuijs, E. R. Van Wering, R.A. de Weger, Jaak M. Vossen, J. J. M. Van Dongen, Marc Bierings, Hein Putter
Publikováno v:
Leukemia, 24(8), 1462-1469. Nature Publishing Group
Leukemia, 24(8), 1462-9
Leukemia, 24(8), 1462-1469
Leukemia, 24(8), 1462-9
Leukemia, 24(8), 1462-1469
Relapse of pediatric acute lymphoblastic leukemia (ALL) remains the main cause of treatment failure after allogeneic stem cell transplantation (alloSCT). A high level of minimal residual disease (MRD) before alloSCT has been shown to predict these re
Publikováno v:
Tijdschrift voor Kindergeneeskunde. 77:170-174
Hemofagocytaire lymfohistiocytose (HLH) is een zeldzaam ziektebeeld dat onder andere kan ontstaan bij kinderen die zijn gediagnosticeerd met een maligniteit. In dit artikel worden drie casus besproken van patienten met secundaire HLH bij een malignit
Autor:
R. M. Egeler, Martha A. Grootenhuis, Hendrik M. Koopman, A Lindahl Norberg, C. M. J. Vrijmoet-Wiersma
Publikováno v:
Supportive Care in Cancer
Supportive Care in Cancer, 17(12), 1435-1443. Springer Verlag
Supportive Care in Cancer, 17(12), 1435-1443. Springer Verlag
Goals of work: Pediatric stem cell transplantation (SCT) is a stressful treatment for children with relapsed or high-risk malignancies, immune deficiencies and certain blood diseases. Parents of children undergoing SCT can experience ongoing stress r
Publikováno v:
Pediatric Blood & Cancer. 49:313-317
Background Although delayed red cell engraftment and/or hemolysis have been thoroughly documented in association with ABO incompatibility between donor and recipient in patients undergoing hematopoietic stem cell transplantation (HSCT), there are no
Publikováno v:
Tijdschrift voor kindergeneeskunde. 73:53-57
In de kindergeneeskunde is ‘informed consent’ een belangrijk begrip geworden. Informed consent gaat uit van twee visies op ziekte en behandeling: een professionele visie en een persoonlijke visie. Een arts stelt een indicatie en doet een behandel
Autor:
M.E.L. van der Burg, Hubert B. Gaspar, A.C. Lankester, R M Egeler, Robbert G. M. Bredius, Nico G. Hartwig, M.J.D. van Tol, Thomas G. Gross, L F A Visser
Publikováno v:
Bone Marrow Transplantation, 36(2), 99-105. Nature Publishing Group
X-linked lymphoproliferative disease (XLP) is a rare immunodeficiency caused by mutations in the signaling lymphocyte activating molecule-associated protein/SH2D1A gene and characterized by a dysregulated immune response to Epstein-Barr virus and oth
Autor:
P. Ljungmann, Shimon Slavin, J Cornish, Francesco Locatelli, Franca Fagioli, Paul Veys, Maurizio Miano, R. M. Egeler, Juan Ortega, C Peters, Olivier Hartmann, Giorgio Dini, Pierre Bordigoni, Anna Paola Iori, Rob Wynn, Ranieri Cancedda, Dietrich Niethammer
Publikováno v:
Bone Marrow Transplantation. 35:S3-S8
A recent report, prepared in March 2003, regarding the paediatric transplantation activity registered between 1970 and 2002 in the European Bone Marrow Transplantation (EBMT) database showed a decrease in the number of registrations in 2001 and in 20
Autor:
Lynne M. Ball, Robbert G. M. Bredius, R M Egeler, A.C. Lankester, M.J.D. van Tol, Willem E. Fibbe
Publikováno v:
Bone Marrow Transplantation. 35:S35-S38
For many children with life-threatening hematological diseases, hematopoietic stem cell transplantation (HSCT) is the only curative option. In children lacking a matched related or unrelated donor and with the certainty that, left untreated, death wi
Autor:
R M Egeler, Serge Cremers, Jaak M. Vossen, A.C. Lankester, Juliette Zwaveling, Robbert G. M. Bredius, Lynne M. Ball, Irene M. Teepe-Twiss, J. den Hartigh
Publikováno v:
Bone Marrow Transplantation. 35:17-23
We studied the pharmacokinetics of intravenous busulfan (Bu) in children in order to further optimize intravenous Bu dosing in relation to toxicity and survival. A total of 31 children undergoing Bu-based conditioning for allogeneic SCT were enrolled